US › Healthcare

Viridian Therapeutics Inc (VRDN)

US · Healthcare · Biotechnology

$20.84+7.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$141,000
Revenue YoY
+95.8%
Net profit
$-104.9M
Profit YoY
-20.7%
EPS
$-0.90
EPS estimate
$-1.08
Net margin
-74,397.9%

EPS came in at -0.90 against a street estimate of -1.08 — a beat of 16.7%.

Key statistics

Market cap
$2.13B
Forward P/E
1.0
P/B
4.15
Book value
$4.92
EPS (TTM)
$-3.35
52-week high
$34.29
52-week low
$13.18
50-day MA
$17.95
200-day MA
$23.99
Beta
0.94

Analyst view

Analysts rate Viridian Therapeutics Inc a buy (14 buy, 2 hold, 0 sell out of 16) with an average price target of $36.12.

Shareholding

Insiders
0.14%
Institutions
112.02%

Largest institutional holders

FundStake
FMR Inc13.93%
BlackRock Inc7.09%
Bellevue Group AG6.09%
Vanguard Group Inc5.08%
State Street Corp4.23%
Vanguard Capital Management, LLC3.77%
Fairmount Funds Management LLC3.54%
VR Adviser, LLC3.52%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Viridian Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.